Search research articles
Contact Us
Filters
Showing results (1-10 of 118) with videos related to
Page
of 12
Sort By:
Expert Opinion on Investigational Drugs
|
March 20, 2012
Glufosfamide: can we improve the process of anticancer agent development?
Denis Lacombe
Expert Review of Anticancer Therapy
|
March 11, 2010
AACR-NCI-EORTC International Conference 2009
Ahmad Awada, Denis Lacombe
Chinese Clinical Oncology
|
April 6, 2015
The future of clinical research in oncology: where are we heading to?
Denis Lacombe, Yan Liu
Lancet (London, England)
|
August 29, 2003
European Organisation for Research and Treatment of Cancer's point of view
Françoise Meunier, Denis Lacombe
The Lancet. Oncology
|
October 11, 2018
Does GDPR harm or benefit research participants? An EORTC point of view
Anastassia Negrouk, Denis Lacombe
Personalized Medicine
|
May 20, 2018
Towards personalized medicine in the EU: what is needed to facilitate the complex international clinical research?
Stéphane Lejeune, Denis Lacombe
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2024
Do regulations and policies undermine the social value of independent academic research?
Denis Lacombe, Fábio Cardoso Borges
Chinese Clinical Oncology
|
April 6, 2015
The changing world of drug development: an academic research organization's perspective on the "Seven Wonders" of the future world of anticancer drug development
Yan Liu, Denis Lacombe, Roger Stupp
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2013
How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
Susen Burock, Françoise Meunier, Denis Lacombe
Journal of Cancer Policy
|
May 13, 2022
Accelerating regulatory approval of anticancer therapies: Benefits, drawbacks and recommendations for a more sustainable approach
Robbe Saesen, Denis Lacombe, Isabelle Huys
Page
of 12
Search research articles
Search
Showing results (1-10 of 118) with videos related to
Sort By:
Page
of 12
Expert Opinion on Investigational Drugs
|
March 20, 2012
Glufosfamide: can we improve the process of anticancer agent development?
Denis Lacombe
Expert Review of Anticancer Therapy
|
March 11, 2010
AACR-NCI-EORTC International Conference 2009
Ahmad Awada, Denis Lacombe
Chinese Clinical Oncology
|
April 6, 2015
The future of clinical research in oncology: where are we heading to?
Denis Lacombe, Yan Liu
Lancet (London, England)
|
August 29, 2003
European Organisation for Research and Treatment of Cancer's point of view
Françoise Meunier, Denis Lacombe
The Lancet. Oncology
|
October 11, 2018
Does GDPR harm or benefit research participants? An EORTC point of view
Anastassia Negrouk, Denis Lacombe
Personalized Medicine
|
May 20, 2018
Towards personalized medicine in the EU: what is needed to facilitate the complex international clinical research?
Stéphane Lejeune, Denis Lacombe
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2024
Do regulations and policies undermine the social value of independent academic research?
Denis Lacombe, Fábio Cardoso Borges
Chinese Clinical Oncology
|
April 6, 2015
The changing world of drug development: an academic research organization's perspective on the "Seven Wonders" of the future world of anticancer drug development
Yan Liu, Denis Lacombe, Roger Stupp
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2013
How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
Susen Burock, Françoise Meunier, Denis Lacombe
Journal of Cancer Policy
|
May 13, 2022
Accelerating regulatory approval of anticancer therapies: Benefits, drawbacks and recommendations for a more sustainable approach
Robbe Saesen, Denis Lacombe, Isabelle Huys
Page
of 12